UK Vaccine Network - Global Health Security and Medicines and Healthcare Products Regulatory Agency
Project disclaimer
Description
The UK Department of Health and Social Care (DHSC) is collaborating with the Medicines and Healthcare products Regulatory Agency (MHRA) to deliver a programme of work consisting of two Work Packages, one with UKVN and the other with the Global AMR Innovation Fund (GAMRIF). The Prime Minister established the UK Vaccine Network (UKVN) in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. UKVN has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. GAMRIF was established in 2016 in response to the Review on Antimicrobial Resistance chaired by Lord Jim O’Neill. It is a One Health UK aid fund that supports research and development (R&D) around the world to reduce the threat of antimicrobial resistance (AMR) in humans, animals and the environment by progressing therapeutics, preventatives and diagnostics along the pipeline for the benefit of people in low- and middle-income countries (LMICs). DHSC is making up to £2,700,000 available to the Partners under the provisions of the International Development Act of 2002 to manage and deliver the two Work Packages. Up to £1,000,000 of this will be for Work Package 1 (UKVN) and up to £1,700,000 for Work Package 2 (GAMRIF). The UKVN Work Package Supporting epidemic and pandemic preparedness by expanding the portfolio of research reagents for emerging viruses. Summary: Simple and timely access to high quality research reagents would accelerate the development of vaccines against emerging infectious diseases, particularly for scientists from low and middle-income countries (LMICs), which are frequently the worst affected. To meet this global need, we propose to expand the Centre for AIDS Reagents (CFAR) to become the Centre for Infectious Disease Reagents (CIDR). The existing CFAR repository at the Medicine and Healthcare products Regulatory Agency (MHRA), has successfully been providing a sustained research reagent resource to the scientific community since 1989, supplying more than 8500 vials of reagents to hundreds of organisations globally, in the past 10 years. Using our existing network and successful operating model, we would, with the expansion of scope for CIDR: Encourage leading laboratories to deposit state of the art research materials to our repository; Produce new reagents, primarily recombinant proteins and pseudotyped viruses; Commission new reagents from collaborators, including peptides and monoclonal antibodies. These materials will be prioritized to organisations in LMICs which will benefit from free of charge access. Our proven track record for collaboration, production and distribution of research reagents assures an ongoing legacy resource for research on emerging pathogens.
Location
The country, countries or regions that benefit from this Programme.
Status Implementation
The current stage of the Programme, consistent with the International Aid Transparency Initiative's (IATI) classifications.
Programme Spend
Programme budget and spend to date, as per the amounts loaded in financial system(s), and for which procurement has been finalised.
Participating Organisation(s)
Help with participating organisations
Accountable:Organisation responsible for oversight of the activity
Extending: Organisation that manages the budget on behalf of the funding organisation.
Funding: Organisation which provides funds.
Implementing: Organisations implementing the activity.
- Accountable
- Funding
- Implementing
Sectors
Sector groups as a percentage of total Programme budget according to the OECD Development Assistance Committee (DAC) classifications.
Budget
A comparison across financial years of forecast budget and spend to date on the Programme.